Comprehensive Chronic Care Disease Management of Liver Disease Improves Member Outcomes, Reduces Costs for Employer-Sponsored Benefits Plans and Healthcare Payers As employers struggle to adjust to the “new normal”...
Read More
Enhances patient outcomes, reduces costs associated with metabolic disease management, improves physician practice financial performance Diabetes is one of the leading causes of disability and death in the United...
Read More
In this white paper physician expert Dr. Caroline Apovian M.D., from The Boston Medical Center, provides a comprehensive overview of the obesity and NAFLD epidemic hitting the United States population.
This white paper examines the impact of NAFLD and NASH as both a medical and economic crisis among military and civilian populations, and highlights the VA’s strategy to eradicate liver disease, including its broadened contract with Echosens to include the FibroScan mini+ portable technology
This white paper examines the impact of NAFLD and NASH as both a medical and economic crisis among military and civilian populations, and highlights the VA’s strategy to eradicate liver disease, including its broadened contract with Echosens to include the FibroScan mini+ portable technology
Having some fat in the liver is normal, but when fat accounts for more than five percent of the organ’s weight, it becomes dangerous.
Having some fat in the liver is normal, but when fat accounts for more than five percent of the organ’s weight, it becomes dangerous.
Studies show that liver disease accounts for approximately two million deaths per year worldwide, and with the growing twin epidemics of obesity and Type 2 diabetes mellitus, Non-Alcoholic Fatty Liver Disease (NAFLD) is expected to grow.
